{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:25:47Z","timestamp":1788553547751,"version":"build-2803163510"},"reference-count":36,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[1999,11,1]],"date-time":"1999-11-01T00:00:00Z","timestamp":941414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Int Med Res"],"published-print":{"date-parts":[[1999,11]]},"abstract":"<jats:p>The aim of this study was to determine the long-term efficacy and safety of mizolastine, a new second-generation antihistamine with European approval, in the treatment of perennial allergic rhinoconjunctivitis. In this study, 141 patients were treated with once-daily mizolastine 10 mg or 15 mg in a 5-month open-label extension of a 1-month double-blind, placebo-controlled trial, which assessed once-daily mizolastine 10 mg. Mizolastine significantly reduced the nasal subscore (sneezing, rhinorrhoea, itch; end-baseline \u00b1 SD, \u22122.5 \u00b1 6.3), nasal obstruction (\u22121.2 \u00b1 2.6) and rhinoscopy scores (\u22121.3 \u00b1 2.6), and improved ocular and total nasal scores after 6 months' treatment. Improvement was maintained for the duration of the study with no loss of drug efficacy. Adverse effects were mild with no specific effects associated with prolonged use. These results clearly demonstrate that mizolastine is effective and well tolerated in the long-term treatment of perennial allergic rhinoconjunctivitis. The significant clinical improvement in nasal blockade may reflect mizolastine's histamine\/5-lipoxygenase dual inhibition.<\/jats:p>\n                  <jats:p>El objectivo del estudio fue de evaluar en pacientes con rinoconjuntivitis al\u00e9rgica perenne la eficacia y la seguridad de un nuevo antihistam\u00ednico de segunda generaci\u00f3n licenciado a nivel Europeo. Este estudio fue la prolongaci\u00f3n de un estudio con mizolastine 10 mg, doble ciego, controlado con placebo de un mes de duraci\u00f3n en el cual se incluyeron 257 pacientes. 141 de estos continuaron en esta fase de extensi\u00f3n que dur\u00f3 5 meses. Mizolastine redujo significativamente las subpuntuaciones nasales: estornudos, rinorrea, picor; final\u2013basal \u00b1 ds, \u22122.5 \u00b1 6.3, la obstrucci\u00f3n nasal (\u22121.2 \u00b1 2.6) y las puntuaciones rinosc\u00f3picas (\u22121.3 \u00b1 2.6). El control fue mantenido durante toda la duraci\u00f3n del estudio (6 meses) sin p\u00e9rdida de eficacia. Los efectos secundarios fueron ligeros y no espec\u00edficos de un tratamiento prolongado. Estos resultados demuestran claramente que mizolastine es eficaz y bien tolerada en el tratamiento prolongado de la rinoconjuntivitis al\u00e9rgica perenne. El control, cl\u00ednicamente significativo, de la obstrucci\u00f3n nasal puede ser el reflejo de la doble actividad farmacol\u00f3gica de la mizolastine, acci\u00f3n sobre la histamine y la 5-lipooxigenasa.<\/jats:p>","DOI":"10.1177\/030006059902700603","type":"journal-article","created":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T19:24:12Z","timestamp":1484681052000},"page":"273-285","source":"Crossref","is-referenced-by-count":13,"title":["Mizolastine is Effective and Well Tolerated in Long-Term Treatment of Perennial Allergic Rhinoconjunctivitis"],"prefix":"10.1177","volume":"27","author":[{"given":"GK","family":"Scadding","sequence":"first","affiliation":[{"name":"Royal National Throat, Nose and Ear Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AJ","family":"Tasman","sequence":"additional","affiliation":[{"name":"University Throat, Nose and Ear Clinic, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Murrieta-Aguttes","sequence":"additional","affiliation":[{"name":"Synth\u00e9labo Group, Bagneux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Bachert","sequence":"additional","affiliation":[{"name":"University Hospital, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"And The Riperex Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[1999,11,1]]},"reference":[{"key":"bibr1-030006059902700603","first-page":"S3","volume":"28","author":"Lundback B","year":"1998","journal-title":"Clin Exp Allergy"},{"key":"bibr2-030006059902700603","doi-asserted-by":"publisher","DOI":"10.1053\/ai.1994.v94.a54939"},{"key":"bibr3-030006059902700603","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(94)90349-2"},{"key":"bibr4-030006059902700603","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)63155-9"},{"key":"bibr5-030006059902700603","doi-asserted-by":"publisher","DOI":"10.1159\/000237289"},{"key":"bibr6-030006059902700603","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1997.tb04816.x"},{"key":"bibr7-030006059902700603","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550220048008"},{"key":"bibr8-030006059902700603","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1997.tb04818.x"},{"key":"bibr9-030006059902700603","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7135.917"},{"key":"bibr10-030006059902700603","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1994.tb04246.x"},{"key":"bibr11-030006059902700603","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1997.tb04882.x"},{"key":"bibr12-030006059902700603","first-page":"135","volume":"69","author":"Rosenzweig P","year":"1992","journal-title":"Ann Allergy"},{"key":"bibr13-030006059902700603","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-199810010-00004"},{"key":"bibr14-030006059902700603","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1996.tb04154.x"},{"key":"bibr15-030006059902700603","first-page":"459","volume":"40","author":"Rosenzweig P","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"bibr16-030006059902700603","first-page":"173","volume":"48","author":"Pichat P","year":"1998","journal-title":"Arzneimittelforschung"},{"key":"bibr17-030006059902700603","first-page":"155","volume":"26","author":"Sudo K","year":"1998","journal-title":"Jpn Pharmacol Ther"},{"key":"bibr18-030006059902700603","volume-title":"New Developments in the Therapy of Allergic Disorders and Asthma","volume":"6","author":"Vargaftig BB","year":"1993"},{"key":"bibr19-030006059902700603","first-page":"G179","volume":"48","author":"Goldhill J","year":"1998","journal-title":"Arzneimittelforschung"},{"key":"bibr20-030006059902700603","first-page":"S373","volume":"51","author":"Michel L","year":"1996","journal-title":"Allergy"},{"key":"bibr21-030006059902700603","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1997.tb01026.x"},{"key":"bibr22-030006059902700603","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)63417-5"},{"key":"bibr23-030006059902700603","doi-asserted-by":"publisher","DOI":"10.1177\/030006059802600603"},{"key":"bibr24-030006059902700603","first-page":"101","volume":"34","author":"Bellioni P","year":"1996","journal-title":"Rhinology"},{"key":"bibr25-030006059902700603","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1998.tb03798.x"},{"key":"bibr26-030006059902700603","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1996.tb00092.x"},{"key":"bibr27-030006059902700603","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.1999.tb00802.x"},{"key":"bibr28-030006059902700603","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199400920-00006"},{"key":"bibr29-030006059902700603","doi-asserted-by":"publisher","DOI":"10.1007\/BF02570505"},{"key":"bibr30-030006059902700603","doi-asserted-by":"publisher","DOI":"10.1007\/BF00191164"},{"key":"bibr31-030006059902700603","first-page":"285","volume":"2","author":"Ross RN","year":"1996","journal-title":"Am J Managed Care"},{"key":"bibr32-030006059902700603","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(97)70127-1"},{"key":"bibr33-030006059902700603","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550220021005"},{"key":"bibr34-030006059902700603","first-page":"251","volume":"51","author":"Bousquet J","year":"1996","journal-title":"Allergy"},{"key":"bibr35-030006059902700603","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(85)90100-9"},{"key":"bibr36-030006059902700603","first-page":"423","author":"Lockey RF","year":"1989","journal-title":"Immunol Allergy Pract"}],"container-title":["Journal of International Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030006059902700603","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030006059902700603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:42:27Z","timestamp":1777459347000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/030006059902700603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,11]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1999,11]]}},"alternative-id":["10.1177\/030006059902700603"],"URL":"https:\/\/doi.org\/10.1177\/030006059902700603","relation":{},"ISSN":["0300-0605","1473-2300"],"issn-type":[{"value":"0300-0605","type":"print"},{"value":"1473-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,11]]}}}